TP-05 is under clinical development by Tarsus Pharmaceuticals and currently in Phase II for Lyme Disease. According to GlobalData, Phase II drugs for Lyme Disease have an 80% phase transition success ...

Of course, product launches were another hot topic in the top 10. Kenvue landed two stories there: Tylenol’s “Easy to Swallow” brand extension at no. 5, and Versalie, which provides virtual menopause ...

Tarsus Pharmaceuticals currently markets Xdemvy (lotilaner ophthalmic solution) 0.25%, a novel eye drop approved for treating Demodex blepharitis. The eye drop was approved by the FDA in 2023 and ...

The biotech sector witnessed a see-saw performance in 2024. While the year started on a positive note, much of the gains ...

An expert provides insights into the cost of misdiagnosed Demodex blepharitis and payer considerations for a potential cost-effective treatment. Eric D. Donnenfeld, MD; underscores the ...

Tarsus, they have their lead drug, XDEMVY, which is for a very non-sexy indication of Demodex blepharitis, which are basically the mites on your eyelids. So there are a few off-label treatments there.

Blepharitis refers to inflamed eyelids. This condition has three causes. You may have an overgrowth of bacteria on your eyelids, leading to dandruff-like flakes. You could have an overgrowth of tiny ...

The company's strategic moves appear to be setting the stage for sustained progress in the treatment of Demodex blepharitis. While analysts project continued sales growth, detailed financial ...

XDEMVY (lotilaner ophthalmic solution) 0.25%, formerly known as TP-03, is a novel prescription eye drop designed to treat Demodex blepharitis by targeting and eradicating the root cause of the ...